Exchange: NASDAQ·Updated 06:28 PM EST

MPLT News

News
all
press releases
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Reaffirmed as Buy by Canaccord Genuity Group
Canaccord Genuity Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Maplight Therapeutics in a research note on Tuesday...
MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Reaffirmed as Buy by Canaccord Genuity Group
Canaccord Genuity Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Maplight Therapeutics in a research note on Tuesday...
MarketBeat
More News
The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.
Stocktwits
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.read more...
Benzinga
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (MapLight or the Company) (NASDAQ: MPLT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
Futures Jump As Brent Tumbles Below $90 On Fresh Round Of Iran Ceasefire Optimism A sharp drop in oil prices prompted by a quieter weekend for geopolitics and a pause in?MidEast hostilities also sparked a drop in bond yields and the USD. A?powerful relief rally in stocks and bonds...
Zero Hedge
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout...
Yahoo! Finance: News
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.read more...
Benzinga
HC Wainwright raised shares of Maplight Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat

Advertisement|Remove ads.